1. Home
  2. ADVM vs CLST Comparison

ADVM vs CLST Comparison

Compare ADVM & CLST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • CLST
  • Stock Information
  • Founded
  • ADVM 2006
  • CLST 1922
  • Country
  • ADVM United States
  • CLST United States
  • Employees
  • ADVM N/A
  • CLST N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • CLST
  • Sector
  • ADVM Health Care
  • CLST
  • Exchange
  • ADVM Nasdaq
  • CLST Nasdaq
  • Market Cap
  • ADVM 59.5M
  • CLST 48.8M
  • IPO Year
  • ADVM 2014
  • CLST N/A
  • Fundamental
  • Price
  • ADVM $2.22
  • CLST $12.00
  • Analyst Decision
  • ADVM Strong Buy
  • CLST
  • Analyst Count
  • ADVM 5
  • CLST 0
  • Target Price
  • ADVM $26.40
  • CLST N/A
  • AVG Volume (30 Days)
  • ADVM 430.7K
  • CLST 5.1K
  • Earning Date
  • ADVM 05-14-2025
  • CLST 04-24-2025
  • Dividend Yield
  • ADVM N/A
  • CLST N/A
  • EPS Growth
  • ADVM N/A
  • CLST N/A
  • EPS
  • ADVM N/A
  • CLST 0.57
  • Revenue
  • ADVM $1,000,000.00
  • CLST $11,257,000.00
  • Revenue This Year
  • ADVM N/A
  • CLST N/A
  • Revenue Next Year
  • ADVM $42.58
  • CLST N/A
  • P/E Ratio
  • ADVM N/A
  • CLST $21.12
  • Revenue Growth
  • ADVM N/A
  • CLST 200.91
  • 52 Week Low
  • ADVM $1.78
  • CLST $10.67
  • 52 Week High
  • ADVM $10.14
  • CLST $12.40
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 36.90
  • CLST 62.86
  • Support Level
  • ADVM $2.10
  • CLST $11.62
  • Resistance Level
  • ADVM $2.33
  • CLST $12.00
  • Average True Range (ATR)
  • ADVM 0.24
  • CLST 0.14
  • MACD
  • ADVM 0.03
  • CLST 0.02
  • Stochastic Oscillator
  • ADVM 32.65
  • CLST 50.00

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About CLST Catalyst Bancorp Inc.

Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.

Share on Social Networks: